Kornimate/medical-research-clean huggingface dataset:
the effect of high-intensity focused electromagnetic on urinary incontinence symptoms

Conditions: Urinary Incontinence, Stress Incontinence

Summary: this study is aimed at women's pelvic floor muscles, especially urinary incontinence caused by pelvic floor muscle relaxation or pelvic prolapse, to observe whether the use of (hifem) high-intensity focused magnetic energy chairs can help the pelvic floor muscles after this treatment strengthening to improve the symptoms of urinary incontinence caused by the compression of the sacral nerve plexus caused by the downward movement of the uterus, thereby improving the social life and quality of life of the patient.


Eligibility criteria:
inclusion criteria: 1. women over 20 years old. 2. symptoms of urinary incontinence (including: stress incontinence, urge incontinence). 3. blood tests confirmed that the number of platelets was 150,000-450,000/ul, and the coagulation function (pt) index was normal. exclusion criteria: 1. pregnant and lactating women. 2. patients with acute or chronic cardiovascular disease. 3. patients with acute or chronic infectious diseases. 4. patients with malignant tumors, uterine fibroids, and gynecological cysts, who have been evaluated by doctors as unsuitable. 5. those who have undergone lower abdominal or genital-related surgery and have been evaluated by doctors as unsuitable. 6. patients with pulmonary insufficiency. 7. people with metal and electronic implants (such as: pacemaker, defibrillator, neurostimulator). 8. those with bleeding disorders or receiving anticoagulant therapy. 9. use drug pumps. 10. people with skin allergies or skin diseases. 11. those unable to sign the subject's consent form.
a study to compare subcutaneous versus intravenous mabthera (rituximab) in combination with chemotherapy in patients with chronic lymphocytic leukemia

Conditions: Lymphocytic Leukemia, Chronic

Summary: this randomized, parallel-group, multi-center study will compare the pharmacokinetics and safety of subcutaneous administration of mabthera (rituximab) versus intravenous mabthera in combination with chemotherapy in previously untreated patients with chronic lymphocytic leukemia (cll). the study consists of 2 parts. in part 1, patients who have previously received 4 cycles of intravenous mabthera will receive in cycle 5 intravenous mabthera and in cycle 6 subcutaneous mabthera. in part 2, patients will be randomized to receive either 6 cycles of intravenous mabthera, or 1 cycle of intravenous mabthera and 5 cycles of subcutaneous mabthera. additionally, all patients will receive chemotherapy (fludarabine and cyclophosphamide) on days 1-3 or days 1-5 of every cycle. the anticipated time on study drug is 24 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * patients with treatment-requiring chronic lymphocytic leukemia (cll) * eastern cooperative oncology group (ecog) performance status of 0-1 * life expectancy \>6 months exclusion criteria: * transformation to aggressive b-cell malignancy * history of other malignancy unless the patient was treated with curative intent and has been in remission for more than 5 years prior to enrolment * hiv or hepatitis b positive unless clearly due to vaccination * inadequate liver or renal function * any coexisting medical or psychological condition that would preclude participation in the required study procedures additional exclusion criterion for part 1: * any previous treatment for cll except for up to 4 cycles of rituximab iv in combination with fc chemotherapy as first-line treatment for cll additional exclusion criterion for part 2: * any previous treatment for cll
safety and effectiveness of subconjunctival injection of bevacizumab in the treatment of corneal neovasculization

Conditions: Lipid Keratopathy; Penetrating Keratoplasty; Herpetic Keratopathy; Rosacea

Summary: 1. purpose:our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. the purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization. 2. material and methods: we enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during aug. 2007 to jan. 2008. subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response. 3. main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.


Eligibility criteria:
inclusion criteria: * significant unilateral or bilateral corneal neovascularization that extending over the limbus at least 2mm * the underlying etiologies that caused corneal neovascularization included post penetrating keratoplasty (pkp), trauma, infectious or non-infectious corneal ulcer, post-keratoplasty, etc. * corneal neovascularization induced lipid keratopathy, corneal edema, or irregular corneal surface. the best-corrected visual acuity was less than 20/25 * post-pkp corneal neovascularization that had no associated lipid keratopathy, no corneal edema, or corneal irregularity. but the neovascularization was highly possible to cause graft rejection. * the corneal neovascularization was refractory to other medical treatment * the patient had received pkp or other corneal surgeries more than half a year ago and was not in the acute post-operation phase * the patient had no active endopthalmitis, glaucoma with uncontrolled intraocular pressure, or vitreoretinal diseases * the patient signed inform consent to have regular follow up and treatment exclusion criteria: * the neovascularization had clinical improvement three months before the first injection * the lipid keratopathy had clinical improvement three months before the first injection * the patient that suspected to have poor visual outcome or had already been light sense negative * glaucoma patient that had uncontrolled intraocular pressure * poor corneal epithelialization * post-pkp patient that had graft failure or rejection * patient that had systemic disease which was not suitable for bevacizumab use * pregnant patient

Keywords: corneal neovascularization lipid keratopathy penetrating keratopathy bevacizumab avastin subconjunctival injection
women engaging in quitting smoking together (we quit)

Conditions: Smoking Cessation

Summary: the long-term goal of this program of research is to develop and disseminate an efficacious intervention for weight concern that will significantly increase smoking cessation rates among women. the overall objective of this project is to develop this intervention and modify it based on piloting and feedback to ensure its feasibility and acceptability. these objectives will be accomplished by pursuing the following specific aim: 1) develop a group-based distress tolerance treatment for weight concern (dt-w) in female smokers and a comparison health education (he) program and pilot both treatments with three groups of 10 (total n = 30) female weight-concerned smokers (2 dt-w groups, 1 he group).


Eligibility criteria:
inclusion criteria: * female * 18 to 65 years of age * smoke 10 or more cigarettes per day * daily smoker for at least the past year * report motivation to quit smoking in the next month of at least 5 on a 10 point scale * report concern of at least 50 on at least one of two 100 point scales assessing weight concern * able to travel to study location for study appointments exclusion criteria: * current use of other smoking cessation or weight loss therapies * current use of other tobacco products at least weekly * current diagnosis of depression * diagnosis or treatment for non-nicotine substance use disorder with substance use during the past 6 months * lifetime diagnosis or treatment of eating disorder, bipolar disorder, schizophrenia, or schizoaffective disorder * current use of psychotropic medication except antidepressants * score above established cut-offs on self-report screening measures of depressive symptomology, eating disorder symptomology, alcohol use disorder, or drug use disorder * current suicidality or homicidality * medical condition that is a contraindication for the use of transdermal nicotine patch * lives at same address as current or past participant

Keywords: smoking cessation women
relationship between delayed cord clamping at birth and neonatal bilirubin levels in parturients with a prior child requiring therapy for neonatal jaundice

Conditions: Hyperbilirubinemia, Neonatal; Jaundice, Neonatal

Summary: the purpose of the study is to determine if neonates (who already have an increased risk of hyperbilirubinemia due to mother's history of having previous neonate who received phototherapy for hyperbilirubinemia) have higher bilirubin levels 24 hours after birth with delayed cord clamping.


Eligibility criteria:
inclusion criteria: * mothers delivering at 35 weeks or greater * mothers who have had at least 1 previous child that received phototherapy for hyperbilirubinemia * multiple gestations can be included unless the neonate does not meet criteria for delayed cord clamping as described below or due to concerns about safety of delayed cord clamping for timing of delivery of the 2nd twin (ie: 2nd twin requires immediate delivery intervention) exclusion criteria: - neonates who do not meet criteria for delayed cord clamping (any infant that any provider in the room felt needed evaluation by the neonatal transport team immediately so that the infant would be handed off for resuscitation. if the patient required delivery by cesarean section the delayed cord clamping protocol would be abandoned).
clinical effect of aprf with dfdba compare to collagen membrane with dfdba in intraosseous defect

Conditions: Intrabony Periodontal Defect

Summary: to assess the effectiveness of advanced prf in combination of demineralized freeze-dried bone allograft (dfdba) as compared to collagen membrane in combination with demineralized freeze-dried bone allograft (dfdba) treatment of non-contained periodontal intraosseous defects in stage iii periodontitis patients.

treatment of intraosseous periodontal defects represents a clinical challenge; these defects have been detected through clinical and radiographic examination in 18- 51 % of patients with periodontitis. they are often associated with persistent deep pockets and bleeding following conventional periodontal treatment. complex regenerative periodontal therapy is advocated for management of these defects. the outcomes of regenerative periodontal therapy are positively correlated with the morphology of osseous defects. non-contained defects are prevalent clinically and have been reported to have a low regenerative potential.

Eligibility criteria:
inclusion criteria: * stage iii periodontitis patient having at least one tooth with one wall or combined1- to 2-wall intraosseous defect ≥ 3 mm deep (assessed by trans-gingival probing, radiographic examination) with clinical attachment level (cal) ≥ 5mm and pocket depth (pd) ≥ 6 mm. * defect not extending to a root furcation area * vital teeth * non-smokers. * no history of intake of antibiotics or other medications affecting the periodontium in the previous 6 months. * no periodontal therapy carried out in the past 6 months. * able to sign an informed consent form. * patients age between 25 and 50 years old. * patients who are cooperative, motivated, and hygiene conscious. * systemically free according to cornell medical index exclusion criteria: * pregnancy or breast feeding * the presence of an orthodontic appliance * teeth mobility greater than grade i

Keywords: stage iii periodontitis aprf advanced platelet rich fibrin demineralized freeze-dried bone allograft dfdba collagen membrane non-contained intraosseous defects one wall intraosseous defects combined 1- to 2-wall intraosseous defect
safety, tolerability, and pharmacokinetics of single doses of hc022 in healthy subjects.

Conditions: Systemic Lupus Erythematosus

Summary: the primary objective of this phase ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (sc) doses of hc022 in healthy subjects. secondary objectives of study are as follows: to estimate the pk parameters of single-ascending sc doses of hc022 in healthy subjects；to evaluate the immunogenicity of hc022 administered to healthy subjects.

this is a first-in-human study of hc022 to assess safety, tolerability, and pharmacokinetic (pk) and pharmacodynamic (pd) effects of single hc022 doses in healthy subjects.

Eligibility criteria:
inclusion criteria: 1. ability to understand the purpose and risks of the study and provide signed and dated informed consent and comply with study requirements; 2. aged 18 to 55 years old, inclusive, male or female; 3. 3.a body weigh ≥ 50 kg for male , and a body weigh ≥ 45 kg for female, and must have a body mass index between 19 and 28 kilogram per square meter (kg/m2)； 4. be in good health as based on medical history, physical examination, vital signs, laboratory tests, chest radiographs, abdominal ultrasound and 12-lead ecg； 5. all women of childbearing potential and all men must practice highly effective contraception during the study and for 6 months (for female) or 3 months (for male) after their dose of study treatment； exclusion criteria: 1. have participated in other clinical trials within 3 months, or within the 5 half lives of the investigational drug prior to screening, whichever is longer; 2. history of or positive test results at screening for the following: for human immunodeficiency virus (hiv), hepatitis c virus antibody (hcv ab), hepatitis b virus (defined as positive for hbsag or hbcab or hbeag)； 3. history of or current diagnosis of active tuberculosis (tb), or untreated latent tb infection (ltbi) at screening； 4. history of severe herpes infection or zoster viral infection； 5. serious infection, serious injuries, or major surgical procedures within 6 months prior to screening； 6. history of alcohol or substance abuse, a positive urine drug or alcohol test at day -1； 7. history of severe allergic or anaphylactic reactions or history of allergic reactions likely to be exacerbated by any component of the study drug； 8. any disease or conditons that are not suitable for participation in this study as determined by the investigator；
ovulation induction in clomiphene citrate resistant pco women

Conditions: Polycystic Ovary Syndrome; Infertility

Summary: polycystic ovary syndrome (pcos) affects 5-10% of women in childbearing age. hyperinsulinemia contributes to chronic anovulation commonly encountered in women with pcos. the first choice therapy is clomiphene citrate (cc). in cc resistant cases, the american college of obstetrics and gynecology (acog) recommends the use of insulin sensitizer metformin. other insulin sensitizing agents include rosiglitazone and pioglitazone. pioglitazone is said to improve fertility and ovulation in patients with pcos.cc may be associated with poor endometrial thickening due to its antiestrogenic effect. letrozole may improve this condition. in this study we will compare the effect of combined letrozole-metformin with that of combined letrozole-pioglitazone in ovulation induction in cc-resistant pcos women

polycystic ovary syndrome (pcos) affects 5-10% of women in childbearing age. hyperinsulinemia contributes to chronic anovulation commonly encountered in women with pcos. the first choice therapy is clomiphene citrate (cc). in cc resistant cases, the acog recommends the use of insulin sensitizer metformin. other insulin sensitizing agents include rosiglitazone and pioglitazone. pioglitazone is said to improve fertility and ovulation in patients with pcos. cc has a long half-life (2 weeks), and this may have a negative effect on the cervical mucus and endometrium, leading to discrepancy between ovulation and conception rates. there has been a search for a compound capable of inducing ovulation but devoid of the adverse antiestrogenic effects of cc. recent studies have suggested that letrozole, an aromatase inhibitor, does not possess the adverse antiestrogenic effects of cc and is associated with higher pregnancy rates than cc treatment in patients with pcos. in this study the investigators shall compare the effect of combined letrozole-metformin with that of combined letrozole-metformin-pioglitazone in ovulation induction in cc-resistant pcos women.this will be a prospective comparative clinical trial in which 2 groups of women will be generated (groups a and b) using the sealed envelopes randomization method.group a (50 women) will receive: letrozole 2.5 mg/day from 3rd day of the cycle for 5 days and (pioglitazone 15 mg + metformin 850 mg) once daily from 1st day of the cycle for 10 days. group b (50 women) will receive letrozole 2.5 mg/day from 3rd day of the cycle for 5 days and metformin 500 mg three times daily from continuously untill pregncy occurrs. ovulation will be monitored by vaginal ultrasound and serum estrogen and progesterone.

Eligibility criteria:
inclusion criteria: * 20-40 years old * pcos infertile women resistant to cc for 3 cycles exclusion criteria: * presence of medical disorders as diabetes, hypertension, cardiac problems, liver or kidney diseases, hyperprolactinemia or thyroid dysfunction * use of gonadotropins before * previous ovarian drilling * presence of urinary symptoms especially bloody urine
interaction study to assess the pharmacokinetic interaction of oral administration of rifapentine on atripla™ in hiv patients

Conditions: Tuberculosis

Summary: primary objective: - to evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (atripla™ ). secondary objective: - to evaluate the safety and tolerability of concomitant administration of rifapentine and atripla™ given to hiv+ patients

* screening to admission: up to 21 days * admission to the end of the follow-up: up to 41 days * period 1: treatment period of 15 days with atripla™ (background therapy). patients should receive the same regimen and dose of atripla™ during the all study screening and period 1. * period 2: treatment over a period of 21 days in co-administration with rifapentine. * follow up: 3 to 5 days after the last rifapentine administration.

Eligibility criteria:
inclusion criteria : - hiv+ male and female patients receiving atripla™ aged 18 to 55 years old with a cd4 count cells of at least 350 exclusion criteria: * any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological (patients with porphyria), neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness other than hiv disease. * active or latent tuberculosis infection the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
modafinil augmentation therapy for excessive daytime sleepiness and negative symptoms in patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to test the effect of modafinil on the negative symptoms, such as blunted affect and social withdrawal, of schizophrenic patients and to determine modafinil's effect on excessive daytime sleepiness. a secondary purpose of the study is to examine the effect of modafinil on cognitive functioning of schizophrenic patients.

twenty six male patients with schizophrenia (twelve with excessive daytime sleepiness and twelve without) will be enrolled at the san diego veterans affairs medical center. modafinil has been shown to increase alertness in individuals who are pathologically sleepy (study c1538a/301/naius). subjects will be randomized in a 1:1 ratio, stratified by excessive daytime sleepiness (value of \>=9 on the epworth sleepiness scale). subjects will receive either modafinil or placebo, supplied by the sponsor. the study drug will be taken by mouth once daily in the morning. the titration schedule will be as follows: 1. the beginning does will be 50mg for 2 weeks 2. the study medication will be increased to 100mg at the week 2 study visit 3. the study medication will be increased to 200mg at the week 4 study visit and will continue for the remaining 4 weeks of the study. if subjects are unable to tolerate dosage increases, the dose will be decreased to the previous level.

Eligibility criteria:
inclusion criteria: * subjects must be able to communicate and give voluntary informed consent * subjects must be of the male gender * between the ages of 18 to 65 years. * a diagnosis of schizophrenia or schizoaffective disorder as determined by dsm-iv criteria. * not conservatorized * a negative symptom score on the panss of \>= 20 and an mmse score of \>24 * no clinical evidence of a current unstable medical illness * no current clinical evidence or past history of cerebral neurological impairment (including strokes, tumors or trauma leading to loss of consciousness) * no history of drug or alcohol dependence in the past 2 years * no evidence of drug or alcohol abuse in the past year, as determined by the dsm-iv criteria. * no diagnosis of narcolepsy as determined by dsm-iv criteria * must have an approved contact person for the duration of the study * may be on a stable dose of ssri for depressive symptoms * no history of aggression * no uncontrolled hypertension, as defined below (subjects cannot have any of the following): 1. a new diagnosis of hypertension, or 2. a change in antihypertensive medications in the past 30 days, or 3. acute hypertension (systolic\>160mmhg, diastolic\>100mmhg) * maybe on a stable dose of a benzodiazepine * the following medications will not be allowed during the study- methylphenidate, amphetamines, pemoline, zolpidem, mao inhibitors, anticoagulant, tca's, or barbiturates. * be on a stable does of an atypical neuroleptic * may be on a stable does of an anticonvulsant for mood stabilization exclusion criteria: * subjects cannot be female.

Keywords: excessive daytime sleepiness
tolerability/pop study in allergic rhinitis after intranasal administration of azd8848

Conditions: Allergic Rhinitis

Summary: the primary purpose is to investigate tolerability/safety of repeated weekly doses of azd8848 administered intranasally to seasonal allergic rhinitis patients.


Eligibility criteria:
inclusion criteria: * patients with a history of birch and/ or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test) * patients with need of treatment for their nasal symptoms during the pollen season exclusion criteria: * clinical relevant disease or abnormality (past or present) - other than allergic rhinitis * symptomatic perennial allergic or non-allergic rhinitis * a history of asthma

Keywords: patients allergic rhinitis tolerability safety nasal symptoms
personalized patient and caregiver education after stroke

Conditions: Stroke, Acute; Stroke, Ischemic; Stroke

Summary: this is a randomized pilot trial to evaluate the impact of a customizable stroke education app (vs standard of care discharge education) on patient satisfaction and education retention. the impact of the intervention will be assessed 7, 30, and 90 days post-discharge.


Eligibility criteria:
inclusion criteria: * admitted for ischemic stroke * at least 18 years old * patient or caregiver has access to a smart phone, tablet or computer * being discharged to either home or acute rehab exclusion criteria: * patient or caregivers unable or unwilling to access the customized app with a smartphone, tablet, or computer * being discharged to a skilled nursing facility * moderate-to-severe aphasia at the time of enrollment (as per nihss scoring) if patient is being enrolled without a caregiver